Fred Aslan re­turns to biotech as pres­i­dent of Vi­vid­ion; Zai Lab scoops Por­to­la's Tao Fu to spear­head US op­er­a­tions

→ Af­ter a stint as CEO of a med­ical de­vice com­pa­ny, Re­cep­tos co-founder and Ven­rock alum Fred Aslan is back in the drug de­vel­op­ment busi­ness. As pres­i­dent and chief busi­ness of­fi­cer of Vi­vid­ion Ther­a­peu­tics, he will play a cru­cial role in en­gi­neer­ing deals to fi­nance the mul­ti­ple ap­pli­ca­tions of Vi­vid­ion’s syn­thet­ic and pro­teom­ic chem­istry plat­forms, which has al­ready scored a big col­lab­o­ra­tion with Cel­gene. Vi­vid­ion has al­so wooed Lar­ry Burgess — long­time ex­ec at Ar­ray Bio­phar­ma — to be­come its head of chem­istry.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER